STING1 and neoplasm: A dual strategy combining low‐level light (LLL) therapy with a nanoscale stimulator of interferon genes (STING) agonist formulation (nanoSTING@Mn) is presented to enhance immune activation and metabolic fitness for durable tumor immunity against T‐cell lymphoma (EL4) model.